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Abstract
Background: The Hippo/MST1 signaling pathway plays an important role in the regulation of cell proliferation and
apoptosis. As a major downstream target of the Hippo/MST1 pathway, YAP2 (Yes-associated protein 2) functions as a
transcriptional cofactor that has been implicated in many biological processes, including organ size control and cancer
development. MST1/Lats kinase inhibits YAP2’s nuclear accumulation and transcriptional activity through inducing the
phosphorylation at serine 127 and the sequential association with 14-3-3 proteins. However, the dephosphorylation of YAP2
is not fully appreciated.
Methodology/Principal Findings: In the present study, we demonstrate that PP1A (catalytic subunit of protein
phosphatase-1) interacts with and dephosphorylates YAP2 in vitro and in vivo, and PP1A-mediated dephosphorylation
induces the nuclear accumulation and transcriptional activation of YAP2. Inhibition of PP1 by okadiac acid (OA) increases
the phosphorylation at serine 127 and cytoplasmic translocation of YAP2 proteins, thereby mitigating its transcription
activity. PP1A expression enhances YAP2’s pro-survival capability and YAP2 knockdown sensitizes ovarian cancer cells to
cisplatin treatment.
Conclusions/Significance: Our findings define a novel molecular mechanism that YAP2 is positively regulated by PP1-
mediated dephosphorylation in the cell survival.
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Introduction
Hippo/MST signaling pathway has been delineated as a tumor
suppressor pathway, which has been implicated in the diverse
biological processes including cell proliferation, apoptosis, organ
size control, and cancer development in both Drosophila and
mammals [1,2,3]. MST1 and MST2 (mammalian STE-20 like
kinase 1 and 2) are key components of the Hippo/MST1 tumor
suppressor pathway [4,5], and we have reported that MST1
mediates oxidative stress-induced neuronal cell death through
phosphorylating FOXO3a at serine 207 [6]. Others and we also
showed that PI3K/Akt and JNK regulate MST1 activation
through protein interaction and phosphorylation during stress-
induced cell death [7,8,9].
YAP2 was initially identified as a Src/Yes kinase associated
protein [10]. Structurally, YAP2 contains one TEAD (TEF
domain) binding domain in the N-terminus followed by two
WW domains and PDZ binding motif in the C-tail [11,12].
Multiple lines of evidences have shown that YAP2 functions as a
transcriptional co-activator and downstream target of the Hippo/
MST pathway in the biological processes of cell size control,
proliferation and cell death[1,2,3,13]. It has recently been shown
that Mst1/2 ablation leads to hepatocellular carcinomas and the
inhibition of YAP2 by MST kinases are an important mechanism
in tumor suppression, especially in the progression of HCC
(hepatocellular cancer) [14,15,16]. Interestingly, YAP2 was
observed in nucleus in a panel of solid tumors, including liver,
breast, ovary and prostate carcinomas [17,18,19,20]. Together,
these findings suggest that YAP2 functions as pro-survival factor
and plays an important role in tumorigenesis. There is the striking
conservation of Hippo pathway between Drosophila and mammals.
Yki (Yorkie), the Drosophila orthologue of mammalian YAP2,
promotes cell growth through transcriptionally co-activating
Sd (Scalloped, Drosophila orthologue of mammalian TEAD)
[1,21,22,23,24].
It has long been demonstrated that the post-transcriptional
modifications (PTMs) of proteins are important for the regulation
of its function, especially for the transcriptional factors and co-
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reported [20,25]. Recent studies showed that Lats phosphorylates
YAP2 on serine 127 leading to its binding with 14-3-3 proteins
[26], which results in cytoplasmic retention and transcriptional
inhibition of YAP2. Consistently, the S127A (serine replaced with
alanine) mutation retains YAP2 in the nucleus and increases its
transactivation, resulting in the cell overgrowth and the epithelial
mesenchymal transition [27,28]. Taken together, the phosphory-
lation and dephosphorylation of YAP2 dynamically regulates its
biological function. However, the dephosphorylation of YAP2
remains unclear.
The phosphoprotein phosphatase superfamily members include
PP1, PP2A (PP2), PP2B (PP3), and PP4–7, among which PP1 is a
major eukaryotic Ser/Thr protein phosphatase that involved in a
variety of biological processes [29,30]. TAZ, a mammalian YAP2
homologue [31], has been shown to be dephosphorylated by PP1A
(catalytic subunit of PP1). By cooperating with ASPP2 (apoptosis
stimulating protein of p53-2), PP1A increases TAZ-mediated gene
expression [32,33]. Most recently it has been reported that a-
catenin regulates Yap1 activity and phosphorylation by modulat-
ing its interaction with 14-3-3 proteins and PP2A phosphatase
[34].
In this study, we identify PP1A, as a component of YAP2
protein complex, regulates YAP2 function in the DNA damage-
induced cell death. We found that PP1A and YAP2 interact with
each other in vitro and in vivo and that PP1A dephosphorylates
YAP2 at serine 127 and dissociates it from 14-3-3 binding, thus
leading to its nuclear retention and transcriptional activation. We
also observed that YAP2 expression inhibits ovarian cancer cell
death induced by cisplatin treatment and the inhibition of PP1A
with okadiac acid increases the phosphorylation and cytoplasmic
translocation as well as the drug resistance capability of YAP2.
Our findings demonstrate that YAP2 is functionally regulated by
PP1A-mediated dephosphorylation.
Results and Discussion
PP1A Interacts with YAP2 in vitro and in vivo
To gain the further understanding of molecular mechanism
underlying YAP2 regulation, we undertook the biochemical
purification of YAP2. We generated stable HeLa cells expressing
human YAP2 tagged with both the FLAG and haemagglutinin
(HA) epitopes at its amino terminus. Cytoplasmic and nuclear
extracts from these cells were subjected to sequential purification
with anti-FLAG and anti-HA antibody columns. As shown in
Figure 1A, several polypeptides were found to be specifically
associated with the YAP2 (compared with the vector control),
whose identities were determined by mass spectrometry. By mass
spectrometry analysis, we identified several known YAP2-inter-
acting proteins including Lats1/2, AMOTL1/2, ASPP1/2 and
TEAD1-4 [35,36,37] in the cytoplasmic or nuclear fraction
(Figure 1B). Notably, PP1A, an unappreciated YAP2 interacting
protein, existed in both cytoplasmic and nuclear fractions
(Figure 1B).
To further define PP1A as a YAP2 complex protein, we
performed glycerol-gradient sedimentation and gel-filtration
experiments. PP1A sedimented together with YAP2 (Figure 1C,
peak fractions 26-30). We defined the interaction between PP1A
and YAP2 in GST pull-down assays by using recombinant GST
fusion proteins (Figure 1D). Upon expression in 293T cells, tagged
YAP2 associated with either exogenous or endogenous PP1A
(Figure 1E and 1F). Consistently, endogenous PP1A and YAP2
form a physical complex (Figure 1G). Taken together, these results
suggest that YAP2 interacts with PP1A.
YAP2 is Dephosphorylated by PP1A in vitro and in vivo
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increases its association with 14-3-3 proteins, which leads to the
cytoplasmic translocation and transcriptional inhibition of
YAP2 [3,38]. Due to the fact that phosphatase PP1A was
identified as a YAP2 interacting protein, we asked whether
YAP2 could be dephosphorylated by PP1. To address this issue,
we performed the in vitro kinase assay by incubating the
recombinant YAP2 proteins with the immunoprecipitated Lats2
kinase, followed by in vitro dephosphorylation assay using
recombinant GST fusion protein encoding PP1A. We found
that Lats2 phosphorylated YAP2 at serine 127 and PP1A
dephosphorylated it (Figure 2A). We next expressed the
exogenous PP1A together with YAP2 and PP1A expression
reduced the pS127 levels of YAP2 in cells (Figure 2B).
Expression of PP1A significantly reduced the endogenous
phospho-S127 levels of YAP2 (Figure 2C). Furthermore,
okadaic acid (phosphatase inhibitor) treatment increased
YAP2 phosphorylation at serine 127 (Figure 2D). Taken
together, these results support the conclusion that PP1A
dephosphorylates YAP2 at serine 127.
PP1A-mediated Dephosphorylation Promotes YAP2
Nuclear Accumulation
It has been reported that serine 127 phosphorylation of YAP2
leads to the 14-3-3 binding and cytoplasmic translocation [3,38]. It
has been shown that 14-3-3 binding plays an important role in the
regulation of YAP2 subcellular localization [38]. We examined the
role of the PP1-mediated dephosphorylation of YAP2 in the
inhibition of YAP2’s interaction with 14-3-3 proteins. While
expression of PP1A robustly disrupted the interaction of 14-3-3
proteins with YAP2 (Figure 3A), okadaic acid (OA) treatment
increased the interaction between YAP and 14-3-3 (Figure 3B). To
determine whether PP1A affect YAP2 subcellular localization, we
performed the nuclear and cytoplasmic fractionation assays. As
expected, PP1A expression increased the nuclear abundance of
YAP2 proteins (Figure 3C). Consistently, PP1A expression
reduced YAP2’s nuclear accumulation and OA treatment
increased the cytoplasmic translocation of YAP2 proteins
(Figures 3D and 3E). Interestingly, we observed that the YAP2
protein level was increased when co-expressed with PP1A after
protein synthesis inhibition by treating cells with Cycloheximide
(CHX) (Figures 3F and 3G), which suggests that dephosphor-
ylatioin of the YAP2 protein increases its stability. These results
suggest that PP1A-mediated dephosphorylation of YAP2 triggers
the dissociation of YAP2 from 14-3-3 proteins and leads to its
nuclear accumulation.
PP1A-induced Dephosphorylation of YAP2 Positively
Regulates the Transcriptional Activity and Prosurvival
Capability of YAP2.
The identification of a signaling link between PP1 and YAP2
that leads to the nuclear accumulation of YAP2 raised the
possibility that PP1-induced YAP2 dephosphorylation might
modulate YAP2-dependent gene transcription and cell survival.
We took advantage of 3*Sd-LUC reporter system [23] to examine
the effect of PP1 expression on the YAP2 co-transcriptional
activity. While PP1A expression significantly increased YAP2
activity, OA treatment led to the inhibition of PP1A-induced
upregulation of YAP2’s transcriptional activity (Figure 4A). CTGF
(connective tissue growth factor) is one of the putative YAP2-
TEAD target genes [35,36,37]. PP1A expression further increased
YAP2-mediated upregulation of CTGF expression in quantative-
YAP2 is Gephosphorylated by PP1A
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24288Figure 1. PP1A interacts with YAP2. A. Tandem affinity purification of YAP2 complex was performed as described in methods. The final HA-
eluates from cytoplasmic and nuclear fractions were resolved on SDS-PAGE gels and silver-stained. B. PP1A was identified from the mass
spectrometry analyses of both cytoplasmic and nuclear HA-eluates. The number of peptide hits for PP1A and several known YAP-interacting proteins
are shown. C. Cytoplasmic and nuclear eluates were separated by 10%–40% glycerol gradient gels followed by Western blotting with anti-PP1
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YAP2-mediated transcriptional activation.
It has been demonstrated that YAP functions as an oncoprotein
in a panel of cancers including ovarian, breast and prostate cancer
[17,18,19,20]. In according with those findings, expression of
YAP2 protected A2780 cells from cisplatin-induced cell death
(Figure 4C). Similar to S127A mutant YAP2, co-expression of
PP1A further increased YAP2-mediated cell survival (Figure 4C),
suggesting PP1A act synergistically with YAP2 to enhance ovarian
cancer cell survival and dephosphorylation of YAP2 increased its
pro-survival capability. Accordingly, while stably expressed YAP2
in A2780 cells inhibited cisplatin-induced Caspase-3 cleavage, OA
treatment abolished YAP2’s protective effect (Figure 4D). In
contrast to YAP2 expression, YAP2 knockdown by using shRNA
increased DNA damage-induced cell death (Figure 4E). OA
treatment failed to increase cisplatin-induced cell death as well as
antibody. D. GST-pull down was carried out by incubating the recombinant GST-YAP2 or GST alone proteins with lysates of cells transfected with
FLAG-PP1A and followed by immunoblotting with anti-FLAG antibody. E. Myc-immunoprecipitates from HeLa cells transfected Myc-YAP2 together
with FLAG-PP1A were immunoblotted with anti-FLAG antibody. 2% input was blotted with anti- FLAG, Myc or actin. F. Myc-YAP2 plasmid or the
control vector was transfected in HeLa cells and cell lysates were immunoprecipitated with anti-Myc antibody followed by immunoblotting with anti-
PP1 antibody. 2% input was blotted with anti- PP1, Myc or GAPDH antibody, respectively. G. Endogenous interaction between YAP2 and PP1A.
doi:10.1371/journal.pone.0024288.g001
Figure 2. YAP2 is dephosphorylated by PP1A in vitro and in vivo. A. In vitro kinase assay and dephosphorylation assay was performed as
described in methods. The recombinant GST-YAP2 proteins were incubated with immunoprecipitated LATS2 in the presence of cold ATP at 30uC for
30 minutes. The reaction products were analyzed by immunoblotting with anti-p-S127-YAP2 antibody. The kinase reaction mixture was incubated
with the recombinant GST-PP1A at 37uC for 1 hour and followed by Western blotting with anti-p-S127-YAP2 antibody. PP1 dephosphorylates YAP2 at
S127 in vitro. B. Lysates of HeLa cells transfected with Myc-YAP2 together with FLAG-PP1A or the control vector were immunoblotted with the
indicated antibodies. C. Lysates of cells transfected with FLAG-PP1A or the control vector were blotted with anti-p-S127-YAP2 antibody. PP1A
dephosphorylates endogenous YAP2 at serine 127. D. HeLa cells were transfected with plasmid encoding Myc-YAP2, and then treated with PP1A
inhibitor OA for indicated time periods. The serine 127 phosphorylation levels of YAP2 were determined by Western blotting. E. HeLa cells were
treated with OA for four hours and the cell lysates were analyzed with anti-YAP2 antibody.
doi:10.1371/journal.pone.0024288.g002
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24288Figure 3. PP1A-mediated dephosphorylation promotes YAP2 nuclear accumulation. A. Myc-immunoprecipitates of HeLa cells transfected
with Myc-YAP2 together with PP1A or control vector were immunoblotted with anti-14-3-3b antibody. PP1A expression inhibits the interaction
between YAP2 and 14-3-3. B. Myc-immunoprecipitates of HeLa cells transfected with Myc-YAP2 plasmid or control vector and treated with or without
OA were blotted with anti-14-3-3b antibody. Phosphatase inhibition increases the interaction between YAP2 and 14-3-3 proteins. C. Nuclear and
cytoplasmic fractionation was performed from HeLa cells transfected with PP1A or control vector. The fractionated lysates were immunoblotted with
anti-YAP2, GAPDH or Histone H3 antibody. PP1A increases the nuclear levels of YAP2. D. HeLa cells were transfected with the GFP-YAP2 and treated
with or without 100 nM OA for 4 hours followed by fluorescent microscopy analysis. E. PP1A increases the nuclear accumulation of YAP2 and OA
treatment induced YAP2 cytoplasmic translocation (t-test; n=3, p,0.01). Data are represented as mean 6 SEM. F. HeLa cells were transfected with
Myc-tagged YAP2 together with FLAG-tagged PP1A expression plasmid or the control vector. 24 hours after transfection, cells were treated with
50 mg/ml Cycloheximide (CHX) for different time periods. Equal amounts of total protein lysates were subjected to immunoblotting. G. PP1A
expression stabilized the protein level of YAP2.
doi:10.1371/journal.pone.0024288.g003
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24288Figure 4. YAP2 dephosphorylation by PP1A regulates YAP2-mediated transcriptional activation and cell survival in ovarian cancer
cell line. A. HeLa cells were transfected with the expression plasmid encoding YAP2 or PP1A plus the 3*Sd-luc luciferase reporter and renilla
plasmids. The cell lysates were subjected to dual luciferase assay (t-test; n=3, p,0.01). OA indicates that HeLa cells were treated with 100 nM OA for
4 hours. PP1A acts synergistically to activate YAP2-mediated transactivation (t-test; n=3, p,0.01). B. Total RNA was isolated from HeLa cells
transfected with the plasmids as indicated. The expression of CTGF was determined by relative quantitative RT-PCR and normalized to GAPDH. PP1A
increases the expression of CTGF (t-test; n=3, p,0.01). C. A2780 cells were transfected with YAP2 or YAP2-S127A plasmid together with or without
PP1A. Cell death was analyzed after 24-hour cisplatin treatment followed by flowcytometry (t-test; n=3, p,0.05). PP1A acts synergistically with YAP2
to enhance ovarian cancer cell survival. D. Lysates of cells infected with adenovirus YAP2 or the control vector treated cisplatin together with or
without OA were immunoblotted with the antibody for cleaved caspase 3, p-S127-YAP2, YAP2 or Erk1/2, respectively. E. A2780 cells were infected
with the adenovirus encoding YAP2 shRNA or control vector. Cell death was analyzed by flowcytometry after cisplatin treatment for 24 hours
together with or without OA (100 nM) for 4 hours before harvesting (t-test; n=3, p.0.05). F. Cell lysates from (E) were immunoblotted with anti-
cleaved caspase 3 or YAP2 antibody.
doi:10.1371/journal.pone.0024288.g004
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suggest that YAP2 dephosphorylation by PP1A enhances YAP2
transcriptional activation, and PP1A acts synergistically with
YAP2 to promote cell survival in ovarian cancer cells.
In this study, we have discovered a novel regulatory mechanism
of YAP2 by PP1-meidated dephosphorylation. The identification
of PP1A as the YAP2 complex protein suggests PP1A plays an
important role in the regulation of the biological function of YAP2
including pro-survival capability.
Our study implicates that the phosphorylation levels of YAP2 is
dynamically regulated in the process of cell death. Protein
phosphatase PP1 reduces YAP2 phosphorylation at serine 127
and disrupts the association with 14-3-3 proteins, which results in
the nuclear accumulation and transcriptional activation of YAP2.
Activation of YAP2-dependent transcription protects ovarian
cancer cells from cisplatin-induced cell death. Since multiple lines
of evidences have demonstrated that Hippo/MST-Yki/YAP2
signaling is conserved in mammals and Drosophila [1], an important
goal of future studies is to determine whether Yki is regulated by
PP1 in Drosophila.
In agreement with the findings that Yap1 and TAZ are
dephosphorylated and activated by PP2 and PP1, respectively
[39,40], we elucidate that PP1 dephosphorylates YAP2 at serine
127. However, it has been reported that there are multiple
phosphorylation sites on YAP2 proteins induced by Lats or CK
(Creatine kinase) kinase [41]. CK phosphorylates YAP2 and
induces its degradation via TrCP [41]. Our findings also raise the
possibility that PP1 might be involved in the removal of other
phosphorylation sites, namely the CK-mediated phosphorylation,
and inhibit the protein degradation of YAP2. In support of this
hypothesis, we found that PP1A expression stabilized YAP2
protein in our CHX (cyclohexamine)-chase experiments
(Figures 3F and 3G).
Tight junction related proteins, such as AMOLTL1/2 and Patj,
have been shown to modulate YAP2 function in the process of
cellular proliferation and homeostasis [35,36]. Given the fact that
PP1A and YAP2 forms a physical complex together with other
appreciated YAP2 interacting proteins including tight junction
related proteins, it will be interesting to investigate how protein
phosphatase PP1 regulates YAP2 function synergistically with
these tight junction proteins in the process of cellular polarity
establishment and homeostasis maintenance.
Materials and Methods
Reagents and Cell Culture
HeLa cells and Ovarian cancer cells (ATCC) were cultured at
37uC and 5% CO2 Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 10% fetal bovine serum (Invitro-
gen), 100 U/ml penicillin and streptomycin (Gibco). Antibodies of
FLAG (Sigma), Myc (Santa Cruz), PP1A (Epitomics), GST (Santa
Cruz), YAP2 (Santa Cruz), Phospho-Ser127-YAP2 (Cell Signal-
ing), Erk1/2 (Cell Signaling), Actin (SIGMA), GAPDH (SIGMA)
were purchased. Cisplatin, okadaic acid and CHX (Cyclohex-
amine) were purchased from Sigma.
Expression Constructs
3xFLAG- tagged MST1 construct was subcloned in the
pCMV10 expression vector. Myc-tagged YAP2 and Myc-tagged
Lats2 constructs were subcloned into the pCMV-Myc expression
vector. GFP-YAP2 construct is in the GFP-C2 expression vector
and GST-YAP2 and GST-PP1A construct is in the pGEX
expression vector. Ad-YAP2, Ad-GFP, Ad-YAP2 shRNA or Ad-
U6 adenovirus was generated to infect the cells. YAP2 shRNA
targeting sequence: GACAUCUUCUGGUCAGAGA [13], the
sequence was cloned into Ad Basic vector under U6 promoter.
Tandem-affinity purification (TAP) of YAP2 Protein
Complex
TAP assay has been previously described [42,43]. Briefly, 4 liters
of suspension HeLa cells that stably transfected with pOZ-FLAG-
HA-YAP2 were harvested in 50 ml hypotonic buffer (1M Tris-HCl
pH 7.3, 3M KCl, 1M MgCl2) containing protease and phosphatase
inhibitors. Cells were homogenized and the nuclear or cytoplasmic
fractions were collected respectively. YAP2 was immunoprecipitat-
ed fromthenuclearorcytoplasmic extracts byusing the anti-FLAG
and HA beads sequentially and the final eluate was digested with
trypsin and analyzed by mass spectrometry.
Density gradient centrifugation. The precipitated proteins
from TAP were centrifuged in 10%–40% gels as described [44].
Immunoprecipitation and Immunoblotting
Immunoprecipitation and immunoblotting analysis was carried
out as described previously. Briefly, cell lysates were incubated
with the indicated antibodies in the presence of 15 mL of protein
A-protein G (2:1)-agarose beads for 2 hours at 4uC. After washed
four times, the immunoprecipitates were subjected to electropho-
resis. Protein expression was examined by probing Western blots
of total cell lysates or immunoprecipitates with the appropriate
antibodies as noted in the figure legends. Detection of band
intensity was carried out with the ECL Western blotting Analysis
System.
In vitro Kinase Assay and dephosphorylation assay
In vitro kinase reactions were carried out by incubating
immunprecipitated Lats and the recombinant GST-YAP2 for
30 min at 30uC in the presence of 3 mM cold ATP in 30 mlo f
buffer containing 20 mM HEPES (pH 7.4), 10 mM MgCl2,
10 mM MnCl2, 1 mM DTT [45]. In vitro dephosphorylation
assay was performed by incubating the kinase reaction mixture
with the recombinant GST-PP1 or GST only protein for 1 hour at
37uC in buffer containing 50 mM HEPES, 100 mM NaCl, 1 mM
MnCl2, 2 mM DTT, 0.1 mM EGTA and 0.025% Tween 20
followed by the SDS-PAGE gel and immunoblotting with the
indicated antibodies.
Luciferase Reporter Assay
Luciferase activity was measured as described [23] according to
the manufacturer’s guidelines. HeLa cells were cultured in 24-well
plates. 3*Sd binding site artificial-luciferase reporter was co-
transfected with the indicated expression plasmids. 36 hours after
transfection, cells were harvested, and luciferase activity was
measured. All luciferase activities were normalized to Renilla and
repeated for three times.
RNA isolation and real-time PCR assay. Total RNA was
isolated from cultured cells using Trizol reagent (Invitrogen).
cDNA was synthesized by reverse transcription using oligo dT as
the primer and proceeded to real-time PCR with gene-specific
primers in the presence of SYBR Premix Ex Taq (DRR041A;
TaKaRa). The relative abundance of mRNA was calculated by
normalization to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA. Primers sequence used for CTGF is 59-
gcttaccgactggaagacacg and 39- cggatgcactttttgccctt.
Apoptosis Analysis
Cell death assays were performed according to the manufac-
turer’s guidelines (BD Pharmingen). Briefly, cells were cultured in
YAP2 is Gephosphorylated by PP1A
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10% fetal bovine serum for 24 hours, then treated with cisplatin
(20 mM) for 24 hours, both floated and attached cells were
collected. Cells were washed with PBS, and resuspended in
binding buffer containing 5 mL Annexin V followed by flow
cytometry (Beckman Coulter). All the experiments were performed
three times.
Statistical analysis
Statistical analysis of the data was performed with a two-tailed
Student’s t-test. Data are presented as the mean 6 SEM except for
analyses of luciferase assays where mean 6 SD is shown. *P ,0.05
or **P,0.01 denotes statistical significance.
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